Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer

Kamalabadi-Farahani, Mohammad; Vasei, Mohammad; Ahmadbeigi, Naser; Ebrahimi‐Barough, Somayeh; Soleimani, Masoud; Roozafzoon, Reza

doi:10.1080/21691401.2018.1527345

Cited by 30 publications

(17 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, for improvement of the TRAIL elicited anti-tumor effects, combined use of TRAIL with various TRAIL sensitizing components (e.g., synthetic agents and natural products) has represented pronounced therapeutic outcomes. Further, the use of NPs and stem cells, in particular, human mesenchymal stem/stromal cells (MSCs), as TRAIL delivery vehicles has currently attracted rapidly evolving attention ( 30 – 32 ).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

et al. 2021

View full text Add to dashboard Cite

The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted rapidly evolving attention as a cancer treatment modality because of its competence to selectively eliminate tumor cells without instigating toxicity in vivo. TRAIL has revealed encouraging promise in preclinical reports in animal models as a cancer treatment option; however, the foremost constraint of the TRAIL therapy is the advancement of TRAIL resistance through a myriad of mechanisms in tumor cells. Investigations have documented that improvement of the expression of anti-apoptotic proteins and survival or proliferation involved signaling pathways concurrently suppressing the expression of pro-apoptotic proteins along with down-regulation of expression of TRAILR1 and TRAILR2, also known as death receptor 4 and 5 (DR4/5) are reliable for tumor cells resistance to TRAIL. Therefore, it seems that the development of a therapeutic approach for overcoming TRAIL resistance is of paramount importance. Studies currently have shown that combined treatment with anti-tumor agents, ranging from synthetic agents to natural products, and TRAIL could result in induction of apoptosis in TRAIL-resistant cells. Also, human mesenchymal stem/stromal cells (MSCs) engineered to generate and deliver TRAIL can provide both targeted and continued delivery of this apoptosis-inducing cytokine. Similarly, nanoparticle (NPs)-based TRAIL delivery offers novel platforms to defeat barricades to TRAIL therapeutic delivery. In the current review, we will focus on underlying mechanisms contributed to inducing resistance to TRAIL in tumor cells, and also discuss recent findings concerning the therapeutic efficacy of combined treatment of TRAIL with other antitumor compounds, and also TRAIL-delivery using human MSCs and NPs to overcome tumor cells resistance to TRAIL.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

“…29,30 The PDMSCs have a spindle-shaped morphology with multiple mesodermal differentiation. 20 We designed to explore whether MSCs isolated from human placental tissue can differentiate into neural cells using induction medium including RA, cAMP, and forskolin supplementation as a neural induction factor, in one step of induction protocol. The PDMSCs have shown their capability in differentiating into neural-like cells, with this characteristic being identified through morphology, q-PCR, and Immunostaining.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, Flow cytometry result indicated that the cells are positive for CD44, CD73, CD105, and CD90, and negative for CD45 and CD34. 20 The FTIR results showed the presence of both polymers PLLA and PCL in the hybrid nanofibrous scaffold. The peaks at 2948 and 2868 cm -1 are due to the C-H stretching, at 1758 and 1735cm-1 match up to the C=O bonding, and at 1183 cm -1 is due to the C-O bending (Fig.…”

Section: Isolation and Characterization Of Cells From The Placental Tmentioning

confidence: 95%

“…Then, the non-adherent cells were detached from the culture dish by trypsin-EDTA (0.25%) solvent, was applied for subculturing up to 3 passages to reach enough cells for carrying out the next experiments. 20 To confirm the MSCs identity, isolated cells (in the 3 passages) were analyzed for the expression of surface antigens by using antibodies against human CD105, CD73, CD90, CD44, CD34, and CD45 surface antigens(eBioscience, San Diego, CA) by Flow cytometry. To confirm the differentiation potential, the cells were cultured in osteogenic (containing 50 mg ascorbic acid bi-phosphate (Sigma), 100 nM BioImpacts, 2020, 10(2), 117-122 119…”

Section: Isolation Cell Surface and Multipotent Differential Analysmentioning

confidence: 99%

See 1 more Smart Citation

Placenta mesenchymal stem cells differentiation toward neuronal-like cells on nanofibrous scaffold

et al. 2020

View full text Add to dashboard Cite

Introduction: Transplantation of stem cells with a nanofibrous scaffold is a promising approach for spinal cord injury therapy. The aim of this work was to differentiate neurallike cells from placenta-derived mesenchymal stem cells (PDMSCs) using suitable induction reagents in three (3D) and two dimensional (2D) culture systems. Methods: After isolation and characterization of PDMSCs, the cells were cultivated on poly-L-lactide acid (PLLA)/poly caprolactone (PCL) nanofibrous scaffold and treated with a neuronal medium for 7 days. Electron microscopy, qPCR, and immunostaining were used to examine the differentiation of PDMSCs (on scaffold and tissue culture polystyrene [TCPS]) and the expression rate of neuronal markers (beta-tubulin, nestin, GFAP, and MAP-2). Results: qPCR analysis showed that beta-tubulin (1.672 fold; P ≤ 0.0001), nestin (11.145 fold; P ≤ 0.0001), and GFAP (80.171; P ≤ 0.0001) gene expressions were higher on scaffolds compared with TCPS. Immunofluorescence analysis showed that nestin and beta-tubulin proteins were recognized in the PDMSCs differentiated on TCPS and scaffold after 7 days in the neuroinductive differentiation medium. Conclusion: Taken together, these results delegated that PDMSCs differentiated on PLLA/PCL scaffolds are more likely to differentiate towards diversity lineages of neural cells. It proposed that PDMSCs have cell subpopulations that have the capability to be differentiated into neurogenic cells.

show abstract

“…Several reports showed the capacity of engineered MSCs expressing TRAIL (MSC-TRAIL) homing to the tumor microenvironment and inducing significant tumor regression [39,40,41]. The effect of MSC-TRAIL destroying tumors was well described in pre-clinical models of glioblastoma [42], pancreatic tumor [43,44], breast cancer [45,46,47,48], and prostate cancer [49]. However, very few studies reported the anti-tumor efficacy of MSC-TRAIL in lung cancer, and its ability to inhibit cancer stem cells (CSCs) derived from NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer

Fakiruddin

Lim

Nordin

et al. 2019

Cancers

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are emerging as vehicles for anti-tumor cytotherapy; however, investigation on its efficacy to target a specific cancer stem cell (CSC) population in non-small cell lung cancer (NSCLC) is lacking. Using assays to evaluate cell proliferation, apoptosis, and gene expression, we investigated the efficacy of MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) to target and destroy CD133+ (prominin-1 positive) NSCLC-derived CSCs. Characterization of TRAIL death receptor 5 (DR5) revealed that it was highly expressed in the CD133+ CSCs of both H460 and H2170 cell lines. The human MSC-TRAIL generated in the study maintained its multipotent characteristics, and caused significant tumor cell inhibition in NSCLC-derived CSCs in a co-culture. The MSC-TRAIL induced an increase in annexin V expression, an indicator of apoptosis in H460 and H2170 derived CD133+ CSCs. Through investigation of mitochondria membrane potential, we found that MSC-TRAIL was capable of inducing intrinsic apoptosis to the CSCs. Using pathway-specific gene expression profiling, we uncovered candidate genes such as NFKB1, BAG3, MCL1, GADD45A, and HRK in CD133+ CSCs, which, if targeted, might increase the sensitivity of NSCLC to MSC-TRAIL-mediated inhibition. As such, our findings add credibility to the utilization of MSC-TRAIL for the treatment of NSCLC through targeting of CD133+ CSCs.

show abstract

Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer

Cited by 30 publications

References 47 publications

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

Placenta mesenchymal stem cells differentiation toward neuronal-like cells on nanofibrous scaffold

Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About